Articles from Openwater

Openwater, an open-source medical technology company delivering portable, hospital-grade diagnostic and therapeutic devices, today announced compelling results from a University of Arizona study published in Frontiers in Psychiatry. The study, “Transcranial Focused Ultrasound Targeting the Default Mode Network for the Treatment of Depression” utilized Openwater’s Open-LIFU 2.0 device to deliver targeted, low-intensity transcranial focused ultrasound pulses to the anterior medial prefrontal cortex, a critical region within the brain’s default mode network implicated in persistent negative thought patterns common in depression. Following 11 brief, ten-minute sessions administered over three weeks (less than two hours of total treatment time), significant reductions in depression severity were seen in 45-60% of the 20 participants (using two widely-used assessments of depression severity). Impressively, 35% achieved clinical remission in this brief treatment modality.

Openwater, the open-source medtech company delivering portable diagnostic and therapeutic devices at a fraction of typical costs, announces the appointment of Aaron Timm as Chief Executive Officer. As a former Vivalink executive with more than two decades in clinical leadership, Timm brings the strategic acumen and operational expertise to scale Openwater through its next phase of global growth. Company founder Mary Lou Jepsen will continue to serve as an active Chairperson of the Board, maintaining her focus on advancing Openwater’s mission of making hospital-grade care available to all.

Openwater today announced the acceleration of its plans to commercialize its hospital-grade technology platform that integrates semiconductor physics, light, and sound to diagnose and treat diseases at the cellular level. The company, founded by brain tumor survivor and former Google X, Meta, and "One Laptop Per Child" executive Mary Lou Jepsen, has secured $100 million in total funding from new and existing investors to advance its mission of making advanced medical care accessible worldwide. New and existing investors include Plum Alley Ventures, Khosla Ventures, BOLD Capital Partners, Esther Dyson, and Peter Gabriel, among others.